Rezolute Inc
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for th… Read more
Rezolute Inc (RZLT) - Net Assets
Latest net assets as of September 2025: $147.17 Million USD
Based on the latest financial reports, Rezolute Inc (RZLT) has net assets worth $147.17 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($158.66 Million) and total liabilities ($11.50 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $147.17 Million |
| % of Total Assets | 92.75% |
| Annual Growth Rate | N/A |
| 5-Year Change | 521.2% |
| 10-Year Change | 1748.05% |
| Growth Volatility | 180.26 |
Rezolute Inc - Net Assets Trend (2012–2025)
This chart illustrates how Rezolute Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Rezolute Inc (2012–2025)
The table below shows the annual net assets of Rezolute Inc from 2012 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | $162.13 Million | +33.99% |
| 2024-06-30 | $121.00 Million | +4.16% |
| 2023-06-30 | $116.17 Million | -22.28% |
| 2022-06-30 | $149.47 Million | +472.71% |
| 2021-06-30 | $26.10 Million | +254.37% |
| 2020-06-30 | $7.37 Million | +320.38% |
| 2019-06-30 | $1.75 Million | +144.23% |
| 2018-06-30 | $-3.96 Million | -146.44% |
| 2017-06-30 | $8.53 Million | -2.79% |
| 2016-06-30 | $8.77 Million | -3.10% |
| 2015-06-30 | $9.05 Million | +41.32% |
| 2014-06-30 | $6.41 Million | +253.93% |
| 2013-06-30 | $-4.16 Million | -76778.68% |
| 2012-06-30 | $-5.41K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Rezolute Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 40376478600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $87.00K | 0.05% |
| Other Comprehensive Income | $-7.00K | 0.00% |
| Other Components | $565.90 Million | 349.05% |
| Total Equity | $162.13 Million | 100.00% |
Rezolute Inc Competitors by Market Cap
The table below lists competitors of Rezolute Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Entravision Communications Corporation
F:EV9
|
$165.58 Million |
|
S IMMO AG
VI:SPI
|
$165.62 Million |
|
Eurocell plc
PINK:ECELF
|
$165.67 Million |
|
Dexterra Group Inc
PINK:HZNOF
|
$165.71 Million |
|
Patel Engineering Limited
NSE:PATELENG
|
$165.54 Million |
|
Ranhill Holdings Ltd
KLSE:5272
|
$165.51 Million |
|
BRT Realty Trust
NYSE:BRT
|
$165.50 Million |
|
Vine Hill Capital Investment Corp. Unit
NASDAQ:VCICU
|
$165.44 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Rezolute Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 121,003,000 to 162,127,000, a change of 41,124,000 (34.0%).
- Net loss of 74,412,000 reduced equity.
- New share issuances of 86,404,000 increased equity.
- Other comprehensive income increased equity by 72,000.
- Other factors increased equity by 29,060,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-74.41 Million | -45.9% |
| Share Issuances | $86.40 Million | +53.29% |
| Other Comprehensive Income | $72.00K | +0.04% |
| Other Changes | $29.06 Million | +17.92% |
| Total Change | $- | 33.99% |
Book Value vs Market Value Analysis
This analysis compares Rezolute Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.20x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-06-30 | $-0.07 | $2.56 | x |
| 2013-06-30 | $-33.54 | $2.56 | x |
| 2014-06-30 | $34.13 | $2.56 | x |
| 2015-06-30 | $21.61 | $2.56 | x |
| 2016-06-30 | $17.71 | $2.56 | x |
| 2017-06-30 | $10.33 | $2.56 | x |
| 2018-06-30 | $-3.56 | $2.56 | x |
| 2019-06-30 | $0.99 | $2.56 | x |
| 2020-06-30 | $1.28 | $2.56 | x |
| 2021-06-30 | $3.40 | $2.56 | x |
| 2022-06-30 | $7.67 | $2.56 | x |
| 2023-06-30 | $2.27 | $2.56 | x |
| 2024-06-30 | $2.35 | $2.56 | x |
| 2025-06-30 | $2.13 | $2.56 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Rezolute Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -45.90%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.08x
- Recent ROE (-45.90%) is above the historical average (-210.87%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-48.75K |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-6.31 Million |
| 2014 | -151.88% | 0.00% | 0.00x | 1.16x | $-10.37 Million |
| 2015 | -125.50% | 0.00% | 0.00x | 1.24x | $-12.27 Million |
| 2016 | -170.25% | 0.00% | 0.00x | 1.24x | $-15.81 Million |
| 2017 | -237.77% | 0.00% | 0.00x | 1.25x | $-21.13 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-29.47 Million |
| 2019 | -1736.13% | 0.00% | 0.00x | 6.99x | $-30.59 Million |
| 2020 | -276.08% | 0.00% | 0.00x | 1.49x | $-21.07 Million |
| 2021 | -80.09% | 0.00% | 0.00x | 1.63x | $-23.51 Million |
| 2022 | -27.47% | 0.00% | 0.00x | 1.02x | $-56.01 Million |
| 2023 | -44.58% | 0.00% | 0.00x | 1.06x | $-63.40 Million |
| 2024 | -56.58% | 0.00% | 0.00x | 1.10x | $-80.56 Million |
| 2025 | -45.90% | 0.00% | 0.00x | 1.08x | $-90.62 Million |
Industry Comparison
This section compares Rezolute Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Rezolute Inc (RZLT) | $147.17 Million | 0.00% | 0.08x | $165.55 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |